1. Introduction {#sec1}
===============

Alzheimer\'s is a progressive disease, where dementia symptoms gradually worsen over a number of years, and it accounts for 50--80% of dementia cases. Alzheimer\'s disease (AD) is estimated to affect \~5.2 million Americans --- a number expected to swell to as many as 16 million by 2050. Efforts are in progress to find better ways to treat the disease, delay its onset, and prevent it from developing. Many tools are used to look for signs of AD, including a battery of cognitive and behavioral tests ([@ref30]; [@ref14]; [@ref25]), cerebrospinal fluid (CSF) analysis ([@ref23]; [@ref32]), magnetic resonance imaging (MRI) ([@ref19]; [@ref20]; [@ref12]) and positron emission tomography (PET) scans ([@ref36]; [@ref52]; [@ref29]). Imaging techniques (MRI and PET) and CSF studies have been pointed as candidates for the diagnostic biomarkers of AD.

It has been found that the CSF measures of total tau (T-tau) and amyloid beta (Aβ1-42) levels are individually sensitive though but with lower specificity for AD against other dementia disorders ([@ref6]). Moreover, the CSF Aβ1-42 levels are not easily interpreted because CSF Aβ1-42 is not exclusively brain derived and also its production and clearance are not well characterized. A number of studies have suggested that CSF markers in combination with neuroimaging and neuropsychological tools add to the accuracy of AD diagnosis ([@ref40]; [@ref41]; [@ref47]).

Out of various medical imaging techniques, MRI is the most widely accepted technique to detect the pathological changes in-vivo based on the tissue *T*~2~ and *T*~1~ contrast relaxation properties. However, to date none of the MRI methods has proven to be an accurate in-vivo marker for early diagnosis of AD. Recently, a new MRI technique has been introduced i.e T1rho (T~1ρ~), the spin lattice relaxation time constant in the rotating frame, which determines the decay of transfer magnetization in presence of "spin-lock" radio-frequency field ([@ref10], [@ref8]; [@ref49]). In biological tissues, T~1ρ~ may have contribution from several molecular interactions. It is also possible that more than one interaction may contribute to the T~1ρ~ signal at a time; however, their relative contributions may differ. Such interactions include chemical exchange, dipolar interaction, and J-coupling. T~1ρ~ MRI has capability to probe the protein contents in various tissues such as brain, blood and cartilage.

T~1ρ~ MRI has been previously used to measure the T~1ρ~ relaxation time in the normal human brain, and showed higher range of values compared to the *T*~2~ relaxation time ([@ref10]). Earlier, T~1ρ~ has been used to delineate brain tumors ([@ref4]), characterize breast cancer tissue ([@ref31]), and monitor the level of cartilage degeneration ([@ref38]; [@ref51]). Borthakur et al. have shown the feasibility of T~1ρ~ imaging in evaluating the plaques burden in a mouse model of AD ([@ref7]). Previous studies have shown higher T~1ρ~ value in the medial temporal lobe (MTL) of AD compared to those of mild cognitive impairment (MCI) and control ([@ref24]; [@ref9]).

In the current study, we aim to evaluate the performance of T~1ρ~ and CSF biomarkers in characterization of AD patients from MCI and control subjects. In addition, we also assess any correlation between T~1ρ~ and CSF biomarkers.

2. Materials and methods {#sec2}
========================

2.1. Participants {#sec2.1}
-----------------

Institutional Review Board of the University of Pennsylvania approved the current study protocol. In this study, we have included 27 AD patients (mean age ± SD = 76.8 ± 9.1 years), 17 MCI patients (mean age ± SD = 71.93 ± 8.7 years), and 17 age-matched control subjects (mean age ± SD = 70.2 ± 9.4 years). A standardized clinical assessment including medical history, physical and neurological examination, psychometric evaluation, and brain MRI was performed in all patients. The general cognitive function in each patient was assessed using Mini-Mental State Examination (MMSE) score. Diagnoses was made by a team consisting of neurologist, neuropsychologist, and psychiatrist who performed extensive behavioral, neuropsychological, and neuroimaging assessments. Diagnoses of MCI was made according to the Petersen criteria for MCI ([@ref37]), while the AD patients were diagnosed according to the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer\'s Disease and Related Disorders Association criteria (NINCDS--ADRDA) for probable AD ([@ref33]). Patients with history of irritable bowel syndrome, chronic diarrhea, peptic ulcer, or gastroesophageal reflux disease; cardiac disease; significant electrocardiographic abnormalities; hematologic disorders; hepatic or renal disease; active malignancy within 5 years; or clinically important depressive, neuropsychiatric, cerebrovascular, or respiratory disease were excluded from this study. The control group consisted of patients, who presented to our memory clinic with subjective complaints, and underwent exactly the same diagnostic work-up as the MCI and AD patients.

2.2. Collection of CSF {#sec2.2}
----------------------

CSF samples were obtained from all subjects by lumbar puncture following an overnight fast. Spinal fluid was withdrawn by experienced physician through an atraumatic 25-gauge sprotte needle and immediately transferred to a bar code-labeled polypropylene vial and placed in −80 °C freezer.

2.3. Biomarker analysis using multiplex xMAP (Luminex) technology {#sec2.3}
-----------------------------------------------------------------

The 42 β-amyloid (Aβ1-42), T-tau and P-tau181p levels were measured in sample aliquots using the multiplex xMAP Luminex platform (Luminex Corp, Austin, TX) with Innogenetics immunoassay kit-based reagents (INNO-BIA AlzBio3, Ghent, Belgium). Full details of this combination immunoassay have been previously published ([@ref46]; [@ref39]). Briefly, the Innogenetics kit reagents included well characterized capture monoclonal antibodies specific for Aβ1-42 (4D7A3), T-tau (AT120) and P-tau181p (AT270), each chemically bonded to unique sets of color-coded beads, and analyte specific detector antibodies (HT7, 3D6). Calibration curves were produced for each biomarker using aqueous buffered solutions that contained the combination of 3 biomarkers at concentrations ranging from 56 to 1948 pg/mL for recombinant tau, 27--1574 pg/mL for synthetic Aβ1-42 peptide and 8--230 pg/mL for a tau synthetic peptide phosphorylated at the threonine 181 position (i.e. the p-tau181p standard).

2.4. MRI protocol {#sec2.4}
-----------------

Written informed consent was obtained from each patient before they underwent for MRI. Brain imaging was performed on a 1.5-Tesla Siemens Sonata clinical-scanner (Siemens Medical Systems, Malvern, PA, USA) using a vendor-supplied head coil. T~1ρ~ images were acquired using a fluid-attenuated T~1ρ~ prepared Turbo Spin-Echo pulse sequence ([@ref10]; [@ref9]). The imaging parameters were: TR/TE = 2000 ms/12 ms, TSL (duration of spin lock pulse) = 10, 20, 30, 40 ms, spin lock pulse amplitude of 500 Hz, slice thickness = 2 mm, FOV = 24 × 24 cm^2^, matrix size = 256 × 128, bandwidth = 130 Hz/pixel, and echo train length = 4 for a total imaging time of 6 min for four T~1ρ~ weighted images. To remove the contribution from CSF to T~1ρ~ weighted MR signal, an inversion time (TI) of 860 ms was used. An oblique coronal T~1ρ~ weighted image of a slice perpendicular to the anterior/posterior commissure (AC/PC) plane was obtained. The slice was chosen to include the head of hippocampus. Immediately after T~1ρ~ MRI, the entire volume of each subject\'s brain was imaged in the coronal plane using a *T*~1~-weighted 3D volumetric magnetization prepared rapid acquisition gradient-echo (MPRAGE) pulse sequence with 160 continuous slices. The parameters were TR/TE = 3000 ms/3.5 ms, slice thickness = 1.2 mm, FOV of 240 × 240 cm^2^ and 192 phase encode steps, and flip angle = 8° for a total imaging time of 10 min.

2.5. Data processing {#sec2.5}
--------------------

Images were transformed to a G4 PowerBook computer (Apple Corp., Cupertino, CA) and processed with programs written in the IDL programming language (RSI Corp., Boulder, CO). T~1ρ~ weighted data corresponding to different TSLs were fitted pixel-wise to a mono-exponential decay expression S(TSL) = *S*(0) × exp (−TSL / T1ρ) ([@ref10]; [@ref9]). Pixels whose intensities correlated poorly (*R*^2^ \< 0.95) with the fitting equation were set to zero. Pixels outside of the brain were also set to zero. T~1ρ~ values were automatically calculated from gray matter (GM) and white matter (WM) of the left and right MTL. For brain segmentation, a previously developed method was used to partition the volumetric MPRAGE scans into 92 regions of interest (ROIs) incorporating all major cortical and sub-cortical regions ([@ref15]). For quantitative analysis, 4 regions of interest (ROIs) were defined on T~1ρ~ images i.e. left and right temporal lobes WM and GM. A program written in IDL was used to automatically calculate T~1ρ~ values only from pixels that were classified as GM and WM located either in the left or right MTL.

2.6. Statistical analyses {#sec2.6}
-------------------------

For statistical analysis T~1ρ~ values from left and right MTL were averaged (separately for GM and WM). Descriptive statistics was performed to calculate the mean value of T~1ρ~ and CSF biomarkers for different cohorts (controls, MCI and AD patients). Mann Whitney *U*-test was performed to see the difference for T~1ρ~ and CSF biomarkers between controls, MCI and AD patients. Logistic regression with enter method was performed to measure the prediction rate of T~1ρ~ and CSF biomarkers in classification of AD, MCI and controls. Receiver operating characteristic (ROC) analysis was performed to measure the sensitivity and specificity. We used a default cutoff 0.5 to predict the event. Additionally, discriminant analysis using T~1ρ~ and CSF biomarkers was performed when three groups taken together. Pearson correlations between T~1ρ~ versus CSF biomarkers, T~1ρ~ versus age and between T~1ρ~ versus MMSE scores were also performed. *p* value equal or less than 0.05 was considered statistically significant. All the statistical computations were performed using the Statistical Package for Social Sciences (SPSS) version 16.0 (SPSS Inc., Chicago, USA).

3. Results {#sec3}
==========

The mean MMSE scores in control (29.533 ± 1.19), MCI (25.11 ± 2.68) and AD (19.16 ± 5.57) were significantly (*p* = 0.001, *p* \< 0.001, *p* = 0.002) different among groups. Mean T~1ρ~ and CSF biomarkers values in three groups (control, MCI and AD) are reported in [Table 1](#t0005){ref-type="table"}.

[Fig. 1](#f0005){ref-type="fig"} shows the overlaid T~1ρ~ maps from MTL region (in color) on fluid-attenuated brain T~1ρ~ weighted images of control, MCI, and AD patient. Pixels with higher T~1ρ~ (red) are more prominent in MTL of AD patient. Increased sulcal space in AD patient suggests greater degree of brain atrophy. A lack of signal from CSF implies that the higher T~1ρ~ values in AD patients are not due to free fluid. The error bars show mean WM T~1ρ~ and GM T~1ρ~ values in controls, MCI and AD patients ([Fig. 2](#f0010){ref-type="fig"}).

On comparative analysis, MCI subjects showed higher T~1ρ~, T-tau, P-tau and lower Aβ1-42 compared to control subjects. However, only increase in WM T~1ρ~ (*p* = 0.05) reached to the statistical significant level ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). AD patients showed significantly increased GM T~1ρ~ (*p* = 0.041), WM T~1ρ~ (*p* = 0.005), T-tau (*p* = 0.001), P-tau (*p* = 0.025) and significantly decreased Aβ1-42 (*p* \< 0.001) compared to control subjects ([Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}). In AD patients, only T-tau concentration was significantly (*p* = 0.05) increased over MCI subjects.

Binary logistic regression showed that T~1ρ~ (GM and WM) was able to predict 77.3% controls and 40.0% MCI subjects, whereas CSF biomarkers (T-tau, P-tau and Aβ1-42) predicted 81.8% controls and 46.7% MCI subjects accurately. Combination of T~1ρ~ and CSF biomarkers were able to predict 86.4% controls and 66.7% MCI subjects.

T~1ρ~ predicted 68.2% controls and 73.9% AD patients correctly while CSF biomarkers predicted 77.3% controls and 78.3% AD patients. When T~1ρ~ combined with CSF biomarkers the prediction rate was 81.8% for controls and 82.6% for AD patients.

T~1ρ~ predicted 35.3% MCI subjects and 81.9% AD patients, while the prediction rate was 53.3% for MCI subjects and 83.0% for AD patients using the CSF biomarkers. Combined CSF biomarkers and T~1ρ~ were able to predict 57.3% MCI subjects and 84.6% AD patients.

When combined three groups together, T~1ρ~ and CSF biomarkers were able to classify 54.5% controls, 40% MCI subjects and 65.2% AD patients. These two biomarkers misclassified 31.8% controls as MCI subjects and 13.6% controls as AD patients, while 33.3% MCI subjects were falsely predicted as controls and 26.7% MCI subjects as AD patients. There were false prediction of 8.7% AD patients as controls and 26.1% AD patients as MCI subjects.

On ROC analysis, T~1ρ~ showed greater sensitivity (60%) and less specificity (77%) than CSF biomarkers (53% and 82%) in discriminating MCI from control ([Table 2](#t0010){ref-type="table"}). When delineating AD from control T~1ρ~ showed 82% sensitivity and 71% specificity while CSF biomarkers showed 77% sensitivity and 79% specificity ([Table 2](#t0010){ref-type="table"}).

In all three cohorts, scattered maps between age and T~1ρ~ showed no significant change in T~1ρ~ values with age ([Fig. 3](#f0015){ref-type="fig"}). However, WM T~1ρ~ in MCI subjects and both GM T~1ρ~ and WM T~1ρ~ in AD patients showed an increasing trend with age ([Fig. 3](#f0015){ref-type="fig"}). No significant correlation of CSF biomarkers with age and T~1ρ~ was observed ([Figs. 4--5](#f0020 f0025){ref-type="fig"}). A negative correlation trend between Aβ1-42 and T~1ρ~ was observed in controls and MCI subjects, while in AD patients this correlation showed a positive trend. On the other hand, correlation between P-tau and T~1ρ~ showed a negative trend both in MCI subjects and AD patients.

4. Discussion {#sec4}
=============

In the current study, significantly higher WM T~1ρ~ and GM T~1ρ~ in MTL in brain of AD was observed compared to that of controls, which is in agreement with the previous studies ([@ref24]; [@ref9]). MCI subjects showed significantly higher WM T~1ρ~ compared to controls, which suggests that abnormality occur earlier in WM than GM. Significantly higher GM and WM T~1ρ~ in AD compared to controls imply that in AD abnormality persist both in GM and WM. Higher changes in WM T~1ρ~ compared to GM T~1ρ~ suggest greater abnormality in WM than GM.

Earlier, Borthakur et al., have shown decreased T~1ρ~ with increased plaques burden in mouse model of AD ([@ref7]). Over the last two decades, a number of transgenic AD mouse models have been created which differ in their biochemical profiles and disease progression rates ([@ref18]; [@ref11]). To date it is debatable which model closely relates with the human AD pathology ([@ref18]; [@ref11]). It is possible that the mouse model used earlier by Borthakur et al., may not clearly depict the human AD pathology. Further, an explanation for higher T~1ρ~ in the human AD patients as observed in the current study and other previous studies ([@ref24]; [@ref9]) is only due to the plaques burden is not sufficient. Moreover, in AD, hyperphosphorylation of tau protein leads to the accumulation of neurofibrillary tangles, which results in loss of neurons. Till date no study has been performed to evaluate any relation between phosphorylated tau protein and T~1ρ~ in AD brain. A postmortem study may help to assess correlation between plaques burden, biochemical changes and T~1ρ~ relaxation time in the human brain, and may provide a more precise explanation for increased T~1ρ~ values in the human AD patients.

Majority of studies have reported decreased Aβ1-42, and increased T-tau and P-tau levels in CSF of MCI and AD patients ([@ref23]; [@ref32]; [@ref1], [@ref2]) and our findings are in conformity with those studies. It is widely believed that increased CSF T-tau level reflects neuronal and axonal damage. However, clinical studies have shown that the elevated CSF T-tau level is not specific to AD as it may also be elevated in other neurodegenerative diseases ([@ref3]; [@ref45]). In a recent study, Hampel\'s group reported that when compared with T-tau, P-tau showed better specificity for AD ([@ref21]). It has also been shown that the P-tau\'s level consistently elevated in AD when compared with frontotemporal dementia (FTD), lewy body dementia (LBD), and control ([@ref35]). An adequate explanation for decreased concentration of Aβ1-42 in CSF of AD patients is still lacking. The suggested explanation that it is due to accumulation of Aβ1-42 in plaques is not sufficient, as decreased Aβ1-42 concentration in CSF of patients with Creutzfeldt--Jakob disease without apparent plaque formation has been reported previously ([@ref50]; [@ref34]). Moreover, considerable uncertainty exists with respect to the influence of ageing on CSF biomarkers levels ([@ref16]; [@ref27]). Normal ageing studies have depicted both positive and negative age effects ([@ref1]; [@ref16]; [@ref27]). In the current study, no age related changes in CSF biomarkers were observed.

Medial temporal lobe (MTA) atrophy as observed on MRI is considered to be an early and sensitive marker for AD, and is assumed that it reflects underlying neuronal loss in hippocampus and temporal lobe ([@ref13]; [@ref28]; [@ref17]). However, MTA may also be present in other types of dementia ([@ref44]; [@ref5]) and absence of MTA does not exclude the diagnosis of AD especially in the early stage. Studies have been performed to investigate the cross-sectional relation between CSF biomarkers and atrophy on MRI. Some observed no relation between CSF tau or Aβ1-42 and whole-brain atrophy ([@ref43]), while others found a significant inverse relationship between CSF P-tau and hippocampal volume in MCI ([@ref26]). It has been shown that the increased CSF tau level corresponds to the higher baseline hippocampal volume in AD. The same study has also reported, no significant effect of T-tau level on hippocampal atrophy ([@ref22]).

In the current study, none of CSF biomarkers were significantly change in MCI compared to controls, while WM T~1ρ~ in MCI was significantly higher than controls. Even if T~1ρ~ was significantly higher in MCI it did not appear as a good predictor of MCI. T~1ρ~ in combination with CSF biomarkers improved the prediction rate for MCI (66.7%). Similarly, combined T~1ρ~ and CSF biomarkers showed better prediction rate for control (81.2%) and AD (82.6%) compared to either T~1ρ~ or CSF biomarkers alone. Combined T~1ρ~ and CSF biomarkers were able to discriminate 57.3% MCI and 84.6% AD. A longitudinal study is needed to elucidate the combined clinical utility of these two biomarkers in progression from MCI to AD.

In the current study, no correlation between T~1ρ~ and CSF biomarkers suggests that these two biomarkers are independent to each other and have differential diagnostic efficacy. Longitudinal studies are needed to understand the relationship between T~1ρ~ and CSF biomarkers. No correlation between T~1ρ~ and age was observed which suggests that the increased T~1ρ~ is due to changes in underlying pathology instead of any age related changes.

No correlation between T1ρ and MMSE suggests that the functional changes as measured by T1ρ probably do not exclusively reflect the cognitive impairment. Moreover, the cognitive analysis depends on the patient\'s behavior which could fluctuate with time. A test retest study can be performed to evaluate covariance in the measurement of the MMSE score. On the other hand CSF biomarker analysis reflects the biochemical changes in the CSF not in the actual pathological tissues. The direct measurement of the biochemical changes in the brain tissues associated with the cognitive performance might be better correlated with the MMSE score.

Recently, Watts et al., have evaluated the age dependence changes in GM and WM T~1ρ~ relaxation times in brain of normal human volunteers on a 3-T MRI scanner ([@ref48]). They have observed a positive correlation between WM T~1ρ~ and age while the GM T~1ρ~ showed negative correlation with age. In the current study, both WM T~1ρ~ and GM T~1ρ~ showed no significant correlation with age. This may be due to the fact that in previous study normal subjects with larger range of age have been studied compared to the current study. However, in this study, both WM T~1ρ~ and GM T~1ρ~ in AD and WM T~1ρ~ in MCI showed an increasing trend with age. This may be due to the higher AD related pathology changes with increasing age. In addition, Watts et al. have found \~7--10% lower T~1ρ~ value both in GM and WM compared to the current study. This is due to the reason that previous study has used 3 T MRI, while the current study used 1.5 T MRI, and it is well known fact that with higher field strength T~1ρ~ decreases ([@ref42]).

One of the limitation of the current study is the cross-sectional design, in which the values of two different diagnostic methods were compared in subject with the clinical diagnosis as gold standard. Further, longitudinal study with larger sample size is needed to properly assess the relative value of these markers in tracking changes along the clinical continuum of AD. In conclusion, both CSF biomarkers and T~1ρ~ MRI seem to have incremental value in diagnosis of AD. By applying them together diagnostic accuracy might be increased.

This work was performed at a NIH supported resource center (NIH RR02305) and from a grant from the Pennsylvania State Tobacco Settlement grant (SAP4100027296).

![T1rho (T~1ρ~) contrast from medial temporal lobe overlaid on anatomic fluid attenuated T~1ρ~ weighted images of control (A), medial cognitive impairment (MCI, B), and Alzheimer\'s disease (AD, C) patients. A progressive increase in T~1ρ~ contrast in medial temporal lobe (MTL) region was observed from control to MCI to AD. No T~1ρ~ contrast from CSF was depicted.](gr1){#f0005}

![The error bars show the mean GM and WM T~1ρ~ values from medial temporal lobe (MTL) in control, MCI and AD. (\*\*) indicates the significance difference (*p* \< 0.05) for the mean T~1ρ~ values between two groups.](gr2){#f0010}

![The scattered maps between age and T~1ρ~ values for controls, MCI subjects and AD patients show no significant correlations.](gr3){#f0015}

![The scattered maps between age and CSF biomarkers show no significant change in the CSF biomarkers with age.](gr4){#f0020}

![The scattered maps between T~1ρ~ values and CSF biomarkers depict no significant correlation in any group.](gr5){#f0025}

###### 

Quantitative values of T~1ρ~ relaxation times and CSF biomarkers from control, MCI and AD subjects.

  --------------------------------------------------------------------------------------------
  Group     T~1ρ~ (ms)\   CSF biomarkers (pg/mL)\                               
            (mean ± SE)   (mean ± SE)                                           
  --------- ------------- ------------------------- -------------- ------------ --------------
  Control   86.8 ± 1.8    80.3 ± 2.1                56.9 ± 7.0     26.1 ± 3.6   230.4 ± 11.1

  MCI       91.9 ± 1.2    85.2 ± 1.4                74.0 ± 12.2    30.6 ± 5.1   188.3 ± 16.0

  AD        92.3 ± 1.0    88.7 ± 1.9                103.3 ± 10.8   39.0 ± 4.9   144.9 ± 10.4
  --------------------------------------------------------------------------------------------

ms = millisecond; SE = standard error; CSF = cerebrospinal fluid; pg = picogram; ml = milliliter; MCI = mild cognitive impairment; AD = Alzheimer\'s disease.

###### 

Receiver operating characteristic (ROC) analysis among control, MCI and AD form T1rho and CSF biomarkers.

  Group            Biomarker   AUC    SE     Sensitivity %   Specificity %   95% CI   *p* value   
  ---------------- ----------- ------ ------ --------------- --------------- -------- ----------- -------
  Control vs MCI   T1rho       0.65   0.09   0.60            0.77            0.49     0.82        0.09
  CSF biomarker    0.67        0.09   0.53   0.82            0.50            0.85     0.05        
  Control vs AD    T1rho       0.80   0.07   0.82            0.71            0.65     0.94        0.001
  CSF biomarker    0.83        0.06   0.77   0.79            0.72            0.95     0.001       

ROC = receiver operating characteristic; MCI = mild cognitive impairment; AD = Alzheimer\'s disease; CSF = cerebrospinal fluid; AUC = area under curve; SE = standard error; CI = confidence interval; LB = lower bond; UP = upper bond.
